Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients

The efficacy and safety will be compared between Chiglitazar and Sitagliptin after treatment of 24 weeks.

Inclusion criteria

• Meet the WHO Diagnostic Criteria for Type 2 Diabetes (published on 1999);
• HbA1c≥ 7.5% and ≤ 10.0% after control of diet and exercises;
• Male and female,age between 18 and 70 years;
• BMI between 18.5-35kg/m2;
• Willing to be assigned to any treatment arm and sign inform consent.

Exclusion criteria

• Type 1 diabetes;
• Treated by oral or injective antidiabetic drug before screening, including insulin and herb;
• Fasting plasma glucose > 13.3 mmol/L (240 mg/dL);
• Resistant hypertension [blood pressure above the goal despite adherence to at least 3 optimally dosed antihypertensive medications (including diuretic) of different classes,or blood pressure is controlled to below the goal by at least different classes of drugs];
• Plasma triglyceride > 500 mg/dL (5.65 mmol/L);
• Is treating by fibrates;
• History of diabetic ketoacidosis,diabetic hyperglycemic hyperosmolar syndrome,lactic acidosis, diabetic hypoglycemia; or is currently combined with retinopathy, diabetic nephropathy and diabetic neuropathy;
• Had transient ischemic attack,cerebrovascular accident or unstable angina in the past 6 months;
• History of myocardial infarction or had conducted coronary angioplasty or coronary artery bypass graft surgery;
• Had or is having pancreatic diseases;
• Heart failure (NYHA classification Stage III or IV), or left ventricular hypertrophy indicated by ECG;
• Hepatic diseases such as hepatocirrhosis, active hepatitis,aspartate aminotransferase or alanine aminotransferase > 2.5 fold of the upper limit of the normal range;
• Kidney diseases or serum creatinine exceed the normal range: male > 133 μmol/L or female >108 μmol/L;
• Had malignancy in the past 5 years, not including basal cell carcinoma;
• Had or is currently receiving treatment that can alter blood glucose metabolism, including but not limited to diuretic,hormone (corticotropin or steroids),beta blockers;
• Have the diseases that can alter blood glucose metabolism, including but not limited to active hepatitis, hyperthyroidism,or adrenal tumors;
• Edema with unknown reason;
• Alcohol or drug addiction;
• Had participated other drugs' clinical trials in the 3 months before screening;
• Pregnant or lactic women; or women of childbearing age who are not able to or is not willing to conduct contraception;
• Any condition that make investigator consider the subject is not suitable to participate the trial.